Citation Information :
Bhartiya S, Ichhpujani P, Parmar UP, Kapoor S, Kaundal S. Glaucoma Drug Prescription Pattern in North India: Public vs Private Sector Hospitals. J Curr Glaucoma Pract 2024; 18 (1):16-22.
Background: Glaucoma is an optic neuropathy associated with characteristic structural damage to the optic nerve and associated visual dysfunction that may be caused by various pathological processes. A number of pharmacological agents are used to reduce the intraocular pressure (IOP), involving the usage of two or three medications concurrently. Literature is sparse regarding prescription patterns of antiglaucoma drugs, especially regarding variability in public sector vs private sector hospitals. Drug utilization studies can add insight for crafting rational, affordable, and ocular surface friendly prescriptions.
Aim: This study assessed the prescription pattern in glaucoma patients of a public sector, tertiary care hospital vs a private sector tertiary care hospital.
Materials and methods: In this retrospective study, pertinent data of diagnosed and labeled glaucoma patients were reviewed. Data collected included demographic details, type of glaucoma, number and nature of drugs prescribed, whether innovator or generic drugs were prescribed, if fixed-drug combinations (FDCs) and preservative-free formulations were prescribed. The prescription patterns between the two sectors were compared, as were the prescription patterns between primary open-angle glaucoma (POAG) and primary angle-closure disease (PACD).
Results: A total of 336 prescriptions were evaluated (216 from public sector, group I; 120 from private sector, group II). Travoprost 0.004% was the most prescribed antiglaucoma medication in both group I (30.09%) and group II (38.33%). Brimonidine and brinzolamide (14.17%) was the most prescribed combination in group II, while Brimonidine with Timolol (7.87%) in group I. In group I, Timolol and Travoprost were the most prescribed medications for both PACD and POAG.
Conclusion: This study showed that both public sector as well as private sector tertiary care centers prescribe antiglaucoma medications in tune with current principles of rational drug use. Preservative-free drugs were preferred in both the groups for better adherence.
Montastruc JL, Benevent J, Montastruc F, et al. What is pharmacoepidemiology? Definition, methods, interest and clinical applications. Therapie 2019;74(2):169–174. DOI: 10.1016/j.therap.2018.08.001
World Health Organization (WHO) and International Network for Rational Use of Drugs. How to investigate drug use in health facilities: selected drug use indicators. Geneva, Switzerland: WHO; 1993. (WHO/DAP/93.1).
Hogerzeil HV. Promoting rational prescribing: an international perspective. Br J Clin Pharmacol 1995;39(1):1–6. DOI: 10.1111/j.1365-2125.1995.tb04402.x
Dinesh Kumar B, Raghuram TC, Radhaiah G, et al. Profile of drug use in urban and rural India. Pharmacoeconomics 1995;7(4):332–346. DOI: 10.2165/00019053-199507040-00007
Jadhav PR, Moghe VV, Deshmukh YA. Drug utilization study in ophthalmology outpatients at a tertiary care teaching hospital. ISRN Pharmacol 2013;2013:768792. DOI: 10.1155/2013/768792
Niraj N, Shafiq N, Kaushik S, et al. Naturalistic evaluation of prescription pattern in glaucoma clinic of a tertiary care hospital: a developing country's perspective. J Pharm Bioallied Sci 2021;13(1):83–87. DOI: 10.4103/jpbs.JPBS_324_20
Akbari MR, Kamalipour A, Pakroo M, et al. Prevalence and correlates of polypharmacy, and drug utilization pattern in a semi-urban population: results from the pars cohort study. Arch Iran Med 2023;26(3):156–165. DOI: 10.34172/aim.2023.24
Tanaka F, Shibatani N, Fujita K, et al. Polypharmacy-associated potential contraindications of drug prescriptions in patients with primary angle closure disease in a real-world setting. J Pharm Health Care Sci 2021;7(1):17. DOI: 10.1186/s40780-021-00196-w
Beck AD, Advanced Glaucoma Intervention Study. Review of recent publications of the Advanced Glaucoma Intervention Study. Curr Opin Ophthalmol 2003;14(2):83–85. DOI: 10.1097/00055735-200304000-00005
Meier-Gibbons F, Töteberg-Harms M. Struktur/Funktion/Behandlung beim Glaukom: Fortschritt in den letzten 10 Jahren. Ophthalmologie 2021;118(12):1216–1221. DOI: 10.1007/s00347-021-01505-2
Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108(11):1943–1953. DOI: 10.1016/s0161-6420(01)00873-9
Konstas AG, Schmetterer L, Costa VP, et al. Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review. Expert Opin Drug Saf 2020;19(11):1445–1460. DOI: 10.1080/14740338.2020.1826928
Bhartiya S, Dhingra D. Generics versus brand-named drugs for glaucoma: the debate continues. Rom J Ophthalmol 2020;64(3):239–244. PMID: 33367157.
Foster PJ, Buhrmann R, Quigley HA, et al. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol 2002;86(2):238–242. DOI: 10.1136/bjo.86.2.238
National List of Essential Medicines (NLEM), 2022. https://main.mohfw.gov.in/?q=newshighlights-104 (Section 21; Pg 71). [Accessed 11 December 2023].
